STOCK TITAN

Cullinan Oncology Inc - CGEM STOCK NEWS

Welcome to our dedicated news page for Cullinan Oncology (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cullinan Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cullinan Oncology's position in the market.

Rhea-AI Summary
Cullinan Oncology, a biopharmaceutical company, will participate in upcoming investor conferences including the TD Cowen 7th Annual Fall Oncology Innovation Summit, the Stifel 2023 Healthcare Conference, and the Evercore ISI HealthCONx Conference. Webcasts of these events will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
conferences
-
Rhea-AI Summary
Cullinan Oncology to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Rhea-AI Summary
Cullinan Oncology has announced the dosing of the first patient in a Phase 1 clinical trial for CLN-978, a targeted oncology therapy for relapsed/refractory B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the treatment. CLN-978 has a differentiated profile with high affinity to CD19-expressing cells and offers patient-friendly administration. This marks Cullinan Oncology's fifth program in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
-
Rhea-AI Summary
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. announced the launch of the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and chemotherapy as a potential first-line treatment for adult patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) exon 20 insertion mutation. This trial aims to assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adult patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR exon 20 insertion mutations. Results from a Phase 1/2a clinical trial of zipalertinib in patients with NSCLC harboring EGFR exon 20 insertion mutations demonstrated its therapeutic potential and were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
conferences
Rhea-AI Summary
Cullinan Oncology announces positive clinical data for CLN-619 in Phase 1 study of advanced solid tumors. Monotherapy shows anti-tumor activity and acceptable safety profile. Expansion cohorts to be initiated in endometrial and cervical cancers. Combination study with pembrolizumab ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
Cullinan Oncology Inc

Nasdaq:CGEM

CGEM Rankings

CGEM Stock Data

717.90M
25.88M
6.4%
95.24%
3.33%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cambridge

About CGEM

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.